Professor, Internal Medicine, University of Iowa College of Medicine
Infectious Disease
Dr. Jack T. Stapleton, MD
|
|
Give Review
Doctor Jack T. Stapleton, MD practices Infectious Disease. He went to University of Kansas School of Medicine. He has 1 awards "Regional Top Doctor". Dr. Jack T. Stapleton is a published doctor and has 54 publications published. The lastest was: 'A sequential classification rule based on multiple quantitative tests in the absence of a gold standard.' He accepts Medicare payments and is registered with Medicare.gov.
Publications
- A sequential classification rule based on multiple quantitative tests in the absence of a gold standard.
- Human Pegivirus (HPgV; formerly known as GBV-C) inhibits IL-12 dependent natural killer cell function.
- Tropism of Human Pegivirus (formerly known as GB virus C/Hepatitis G virus)and host immunomodulation: insights into a highly successful viral infection.
- Serological responses to an avian influenza A/H7N9 vaccine mixed at the point-of-use with MF59 adjuvant: a randomized clinical trial.
- GBV-C Infection and Risk of NHL among U.S. Adults.
- Human Pegivirus (HPgV or GB virus C) RNA is found in multiple blood mononuclear cells in vivo and serum-derived viral RNA containing particles are infectious in vitro.
- GB virus C infection and B-cell, natural killer cell, and monocyte activation markers in HIV-infected individuals.
- GB Virus C Particles Inhibit T Cell Activation via Envelope E2 Protein-Mediated Inhibition of TCR Signaling.
- Bayesian analysis and classification of two enzyme-linked immunosorbent assay tests without a gold standard.
- Regulatory B cell frequency correlates with markers of HIV disease progression and attenuates anti-HIV CD8+ T cell function in vitro.
- Chimpanzee GB virus C and GB virus A E2 envelope glycoproteins contain a peptide motif that inhibits HIV-1 replication in human CD4+ T cells.
- GB Virus C Infection Is Associated with Altered Lymphocyte Subset Distribution and Reduced T Cell Activation and Proliferation in HIV-Infected Individuals.
- GB virus C viremia is associated with higher levels of double-negative T cells and lower T-cell activation in HIV-infected individuals receiving antiretroviral therapy.
- Immunogenicity and safety of varying dosages of a monovalent 2009 H1N1 influenza vaccine given with and without AS03 adjuvant system in healthy adults and older perso...
- GB Virus C Envelope Protein E2 Inhibits TCR-Induced IL-2 Production and Alters IL-2-Signaling Pathways.
- GB virus type C infection polarizes T-cell cytokine gene expression toward a Th1 cytokine profile via NS5A protein expression.
- Study design may explain discrepancies in GB virus C effects on interferon-γ and interleukin-2 production and CD38 expression in T lymphocytes.
- Characterization of a peptide domain within the GB virus C envelope glycoprotein (E2) that inhibits HIV replication.
- Evidence against GB virus C infection in dromedary camels.
- GB virus type C envelope protein E2 elicits antibodies that react with a cellular antigen on HIV-1 particles and neutralize diverse HIV-1 isolates.
- GB virus C infection and non-Hodgkin lymphoma: important to know but the jury is out.
- A copula model for bivariate hybrid censored survival data with application to the MACS study.
- Viruses within the Flaviviridae decrease CD4 expression and inhibit HIV replication in human CD4+ cells.
- Imputation methods for doubly censored HIV data.
- GBV-C viremia is associated with reduced CD4 expansion in HIV-infected people receiving HAART and interleukin-2 therapy.
- Low frequency of GB virus C viremia in a cohort of HIV-1-infected elite suppressors.
- Expression of the dengue virus type 2 NS5 protein in a CD4(+) T cell line inhibits HIV replication.
- Coinfection alters the playing field: herpesviruses induce acyclovir to inhibit HIV.
- Characterization of a peptide domain within the GB virus C NS5A phosphoprotein that inhibits HIV replication.
- Selenium effects on HIV RNA and CD4 cell counts.
- Factors associated with seronegative chronic hepatitis C virus infection in HIV infection.
- Characterization of an immunodominant antigenic site on GB virus C glycoprotein E2 that is involved in cell binding.
- An 85-aa segment of the GB virus type C NS5A phosphoprotein inhibits HIV-1 replication in CD4+ Jurkat T cells.
- In vitro interaction between hepatitis C virus (HCV) envelope glycoprotein E2 and serum lipoproteins (LPs) results in enhanced cellular binding of both HCV E2 and LPs.
- HIV and GB virus C coinfection.
- GB virus C replicates in primary T and B lymphocytes.
- South African GB virus C isolates: interactions between genotypes 1 and 5 isolates and HIV.
- GB virus C infection and survival in the Amsterdam Cohort Study.
- GB virus type C NS5A sequence polymorphisms: association with interferon susceptibility and inhibition of PKR-mediated eIF2alpha phosphorylation.
- Vaccination success rate and reaction profile with diluted and undiluted smallpox vaccine: a randomized controlled trial.
- GB virus type C: a beneficial infection?
- Seronegative hepatitis C virus infection, not just RNA detection.
- Active or prior GB virus C infection does not protect against vertical transmission of HIV in coinfected women from Tanzania.
- Persistent GB virus C infection and survival in HIV-infected men.
- Neutralizing human monoclonal antibodies to hepatitis A virus recovered by phage display.
- Clinical isolates of GB virus type C vary in their ability to persist and replicate in peripheral blood mononuclear cell cultures.
- Inaccurate glycosylated hemoglobin A1C measurements in human immunodeficiency virus-positive patients with diabetes mellitus.
- GB virus type C/Hepatitis G virus.
- Recombinant hepatitis C virus-like particles expressed by baculovirus: utility in cell-binding and antibody detection assays.
- Interactions Between GB Virus Type C and HIV.
- Hepatitis C virus viremia in HIV-infected individuals with negative HCV antibody tests.
- Alcohol use and HIV pharmacotherapy.
- Regulatory B Cells Inhibit Cytotoxic T Lymphocyte (CTL) Activity and Elimination of Infected CD4 T Cells after In Vitro Reactivation of HIV Latent Reservoirs.
Schools
University of Kansas School of Medicine
North Carolina Memorial Hospital
Doctors Specialties
- Infectious Disease Medicine
- Infectious Disease
Accepted Insurances
Awards
- Regional Top Doctor
Education
-
University of North Carolina Hospitals -
University of Kansas School of Medicine
Drug Facts
| NPI NUMBER | 1083603773 | |
| NPPES Provider LastName | STAPLETON | |
| NPPES Provider FirstName | JACK | |
| NPPES Provider ZIPCode | 522421009 | |
| NPPES Provider State | IA | |
| Specialty Description | Infectious Disease | |
| Total Claim Count | 1353.0 | |
| Distinct Opioid Count | 3.0 | |
| Opioid Claim Count | 68.0 | |
| Percent Opioid Claims | 5.03 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1083603773 |
| Last Name Of The Provider | STAPLETON |
| First Name Of The Provider | JACK |
| View All |
Similar Doctors
|
Dr. John M. Andreoni, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mary E. Wilson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Philip M. Polgreen, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Loreen A. Herwaldt, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Charles M. Helms, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michihiko Goto, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jeffery L. Meier, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jacob T. Hodges, MD |
|
|
Dr. Lauris C. Kaldjian, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David J. Kusner, MD
This Doctor is OpenDoctor Recommended.
|